AnaptysBio (ANAB) Earnings Forecast
Analysts expect AnaptysBio (ANAB) to earn $4.76 a share in FY26, from the one published estimate as of Nov 16, 2026.
1 figure withheld by our checks. Each blank figure names its reason.
- FY26 consensus EPS
- $4.76
- 1 analyst
- FY27 consensus EPS
- $7.75
- 3 analysts · low $5.16, high $10.10
- EPS revisions, 31 days
- −6.2%
- $5.07 to $4.76
Consensus estimates only. Analysts' price forecasts and ratings are not licensed here.
One analyst covers this company. Every figure on this page is that one person's estimate rather than an average of several, and it moves on one change of mind.
Analysts expect AnaptysBio to earn $8.21 a share in FY30, growing about 15% a year; 1 analyst publishes an estimate for FY30.
Are estimates going up or down lately?
The FY26 EPS consensus is $4.76, up 414.4% in 90 days. Every figure compares one fiscal period at both ends.
EPS consensus, change over the last 90 days. One step per nightly change.
| EPS | 30 days | 90 daysshown above | Since Jul 6 |
|---|---|---|---|
| FY261 analyst | ▼ −6.2%$5.07 to $4.76 | ▲ +414.4%$−1.51 to $4.76 | ▲ +413.0%$−1.52 to $4.76 |
| FY273 analysts | ▲ +14.9%$6.75 to $7.75 | ▲ +296.4%$1.96 to $7.75 | ▲ +296.6%$1.96 to $7.75 |
| Dec '262 analysts | ◆ 0.0%$5.11 to $5.11 | ▲ +53512.8%$−0.01 to $5.11 | ▲ +53512.8%$−0.01 to $5.11 |
| Mar '271 analyst | 23 of 30 days+2.3% so far | 23 of 90 days+2.3% so far | ▲ +2.3%$0.85 to $0.87 |
Contributors at both ends of the window: FY26 5 and 1. A change in the average can come from a new contributor as much as from a changed mind, so both counts stay in view.
Measured between two of our own nightly snapshots of one fiscal period, so a new fiscal year entering the view is never read as a revision. Never backfilled. A window still filling says how many days it holds; a blank one means our record is not that long yet.
If the Street is right, what does that imply for the share price?
Pick a fiscal year and a multiple and the sum runs on the numbers the Street published.
One analyst covers this year, so the estimate is a single number and there is no low to high band to draw around the answer.
This is multiplication, not a forecast. It assumes the market pays the multiple you chose and that the consensus is right. Both are often wrong.
What you pay for the growth
You are paying 9.6 times the FY26 consensus for earnings the one analyst covering it expects to grow about 22% a year to FY28. That is 0.4 times the growth rate.
How much do analysts disagree?
One analyst publishes on each year, so there is no range to draw: the low, the high and the average are one number, and a single mark stands for each year.
The dashed line is FY25 filed $−0.46, on the GAAP basis.
A wide spread is disagreement, not risk; a narrow one is agreement, not accuracy. Later years are always wider because fewer people forecast them. Bars in amber rest on fewer than 15 analysts. The tick on each bar is the average.
Is next quarter a high bar or an easy one?
Analysts expect AnaptysBio to earn $5.11 a share in the December quarter, the average of 2 estimates. Results are expected by Feb 19, 2027.
low $0.95
The step from a filed quarter to a consensus crosses bases: the filed figure is the company's own GAAP number and the consensus is on the Street's basis. It is printed with both bases named, not as growth. For the March quarter, analysts expect $0.87 a share.
Does AnaptysBio usually beat or miss?
We have not been able to check a quarter yet. Our record of estimates for AnaptysBio begins on Jul 6, 2026, and a quarter can be checked only when we hold an estimate for it from before the company reported. The next report is expected by Feb 19, 2027.
We started recording estimates on Jul 6, 2026, so quarters that reported before that date cannot be checked.
Checked against the company's reported figure (GAAP) and the average estimate we recorded the night before its results release. Where analysts' number is on an adjusted basis, we leave the comparison out rather than force it. We started recording estimates for AnaptysBio on Jul 6, 2026, so earlier quarters cannot be checked, and we never fill them in after the fact.
Where the growth comes from
The one analyst covering it expects sales to grow 77.7% in FY27 and EPS 63.0%. Sales do all of it and the other two take some back: the net margin moves from 88.7% to 92.2%, and the implied share count from about 27.3M to 30.9M, so these numbers assume no buyback.Show the decomposition and the margin ladderHide the decomposition
| Revenue growth | +77.7 |
|---|---|
| Net margin change | +6.9 |
| Share count change | −21.6 |
| EPS growth | +63.0 |
Coverage, and the gap to the filing
1 analyst publishes an EPS estimate for FY26 and 1 publishes revenue. Consensus figures are on the Street's basis and filed figures are GAAP; we label the gap, we do not explain it away.Show coverage by year and over timeHide the coverage chart
The full consensus, year by year
Coverage thins with distance: 1 revenue estimates for FY26, 2 for FY30.
Out-year bands widen as fewer analysts publish: 1 EPS estimates for FY26, 1 for FY30.
| Fiscal year | Revenue $B | YoY | EPS $ | YoY | EBITDA $B | Net inc. $B | Shares B | Analysts rev · EPS | Fwd P/E |
|---|---|---|---|---|---|---|---|---|---|
| FY25Filed | 0.2 | — | −0.46 | — | — | — | — | as filed | n/m |
| FY26E | 0.10.1 to 0.2 | ▼37.7%a | 4.763.17 to 6.20 | n/ca | 0.2 | 0.1 | 0.03 | 1 · 1 | 9.6× |
| FY27E | 0.30.2 to 0.3 | n/cb | 7.755.16 to 10.10 | n/cb | 0.4 | 0.2 | 0.03 | 4 · 3 | 5.9× |
| FY28E | 0.30.2 to 0.4 | ▲17.3% | 7.044.96 to 12.70 | n/cb | 0.3 | 0.2 | 0.03 | 5 · 5 | 6.5× |
| FY29E | 0.30.3 to 0.4 | n/cb | 8.085.38 to 10.52 | n/cb | 0.4 | 0.3 | 0.03 | 2 · 1 | 5.7× |
| FY30E | 0.40.3 to 0.5 | ▲18.5% | 8.215.47 to 10.70 | ▲1.7% | 0.4 | 0.3 | 0.03 | 2 · 1 | 5.6× |
Average estimate with low to high beneath. Amber counts mark thin coverage and thin rows carry an amber rule. Shares = consensus net income ÷ consensus EPS, a direction rather than a decimal. The filed row's last column is today's price over that year's filed EPS, the one trailing multiple in that column. a This step crosses the seam: last year is a filed GAAP actual and this year is a consensus estimate, so the two are not prepared on one basis. b More than a third of the analyst panel changed between these two years, so the difference of the two averages measures the panel rather than the forecast.
Analysts' price forecasts and grades are not licensed here. This page shows forward consensus estimates only: 1 EPS estimates for FY26. Not investment advice.
Common questions
What do analysts expect AnaptysBio to earn in FY26?
The one analyst covering AnaptysBio expects it to earn $4.76 a share in FY26, as of Nov 16, 2026.
What is AnaptysBio's earnings forecast for FY27?
The FY27 consensus for AnaptysBio is $7.75 a share from 3 analysts, with a low of $5.16 and a high of $10.10, as of Nov 16, 2026.

